雷贝拉唑、克拉霉素、阿莫西林三联疗法治疗幽门螺杆菌相关性溃疡

目的:评估雷贝拉唑、克拉霉素、阿莫西林三联疗法治疗幽门螺杆菌(Helicobacter pylori,Hp)相关性溃疡的疗效。方法:86例经胃镜检查确诊,并经快速尿素酶法和组织学测定为Hp阳性的消化性溃疡病人,随机分为雷贝拉唑组(46例)和奥美拉唑组(40例)。两组分别予以三联疗法:雷贝拉唑20 mg或奥美拉唑20 mg,bid;克拉霉素0.5 g,bid;阿莫西林1.0 g,bid,连用10 d,记录用药后病人症状缓解程度。疗程结束后4周,复查胃镜并检测Hp。结果:雷贝拉唑组第1、3天症状缓解率分别为65.2%和93.5%;奥美拉唑组为20.0%和45.0%,两组差异有显著性(P<0.05)。雷贝拉唑组溃疡治愈率为95.7%,奥美拉唑组为72.5%,两组比较差异有显著性(P<0.05)。雷贝拉唑组Hp根除率为93.5%,奥美拉唑组为90.0%,两组比较无统计学差异(P>0.05)。结论:雷贝拉唑三联疗法治疗Hp相关性溃疡,溃疡愈合迅速、症状消失快,与奥美拉唑组比较,雷贝拉唑组在症状缓解率及溃疡愈合方面更具优势。

Rabeprazole combined with clarithromycin and amoxicillin in the treatment of Helicobacter pylori-related ulcer

Objective:To evaluate the efficacy of rabeprazole combined with clarithromycin and amoxicillin in the treatment of Helicobacter pylori(Hp)-related ulcer.Methods:Eighty-six patients with peptic ulcer and Hp infection confirmed by gastroscopy and right urease test were randomized to receiving rabeprazole(46 cases)-or omeprazole(40 cases)-based triple therapy regimen for 10 days.The therapeutic regimens were as follows:rabeprazole 20 mg or omeprazole 20 mg,bid;clarithromycin 0.5 g,bid;amoxicillin 1.0 g,bid.The patients' symptomatic relief rate after medication was recorded.Gastroscopy and right urease test were repeated in the fourth week after the end of the treatment.Results:On the first day and the third day of the treatment,the symptomatic relief rate was 65.2% and 93.5% in rabeprazole group,while it was 20.0% and 45.0% in omeprazole group.There were significant differences between the two groups(P<0.05).The ulcer healing rate of rabeprazole group was higher than that of the omeprazole group(95.7% vs 72.5%,P<0.05).Hp eradication rate was 93.5% in rabeprazole group and 90.0% in omeprazole group.There was no significant difference between the two groups(P>0.05).Conclusion:Compared with the omeprazole group,rabeprazole group has better efficacy in ulcer healing and symptomatic relief rate.